Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
Institutional Seminar
Event Information
| Date and Time | 2:00 PM to 3:30 PM on Tuesday, September 30th , 2025 |
|---|---|
| Venue | Large Seminar Room, 8th, General Research Building |
| Speaker | Dr Anna Trigos |
| Affiliation/Position | Peter MacCallum Cancer Centre・Laboratory head |
| Country | Australia |
| Title | Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer |
| Organizer | 〇Lead Organizer:NAKAI Kenta(Laboratory of Functional Analysis in silico) Organizer:FURUKAWA Yoichi(Division of Clinical Genome Research) |
Overview
The evolution from low-grade to metastatic tumour is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the extrinsic microenvironment. To define the key mechanisms underpinning metastatic development, we focused on the metastatic castration-resistant prostate cancer (mCRPC) and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions from 9 patients obtained through rapid autopsy. We found that intra-tumour heterogeneity is an indicator of key evolutionary processes, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. Intra-patient functional convergence of tumour ecosystems was observed across metastases, showing system-level selection pressures that drive the heterogeneity landscape of mCRPC. Our findings reveal functional evolutionary convergence of metastatic disease into units of intra-tumour heterogeneity, identifying critical determinants of metastatic progression for therapeutic targeting.
